Paul Woodard

Nov 20, 2024 | jitc.bmj.com | Matthew Taylor |Aung Naing |John Powderly |Paul Woodard

MethodsThis is a first-in-human, multicenter, open-label, dose-escalation phase I trial (online supplemental file 1). The study evaluated the safety, PK, immunogenicity, clinical efficacy and biomarkers of intravenously administered IO-108 as monotherapy and in combination with pembrolizumab in patients with solid tumors that failed prior therapies.